D. Scott Neal’s Bristol-Myers Squibb BMY Stock Holding History

D. Scott Neal’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-100	Closed	-$6K	–	80
2018 Q1	$6K	Buy	+100	New	+$6.43K	﹤0.01%	137
2017 Q2	–	Sell	-140	Closed	-$8K	–	180
2017 Q1	$8K	Hold	140	–	–	0.01%	124
2016 Q4	$8K	Hold	140	–	–	0.01%	122
2016 Q3	$8K	Hold	140	–	–	0.01%	115
2016 Q2	$10K	Buy	+140	New	+$9.89K	0.01%	110

Other funds holding BMY

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D. Scott Neal's BMY Position: Q2 2018 in Review

D. Scott Neal sold out of Bristol-Myers Squibb (BMY) in Q2 2018, closing a stake of 100 shares — an estimated $6K sold.

D. Scott Neal first reported a position in BMY in Q2 2016 and held it in 5 quarters. The position peaked at $10K in Q2 2016. 1,691 funds tracked by Wall St. Rank hold BMY as of Q2 2018.

D. Scott Neal reported no remaining Bristol-Myers Squibb position as of Q2 2018 after selling out during the quarter.
D. Scott Neal sold 100 Bristol-Myers Squibb shares in Q2 2018, an estimated $6K.
D. Scott Neal first reported a position in Bristol-Myers Squibb in Q2 2016 and held it in 5 quarters.
D. Scott Neal's Bristol-Myers Squibb position peaked at $10K in Q2 2016.
1,691 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2018.

Based on D. Scott Neal's 13F filing for Q2 2018, filed 15 Aug 2018.